|[August 30, 2013]
Ipsen: Detailed results of the phase III CLARINET study at the European Cancer Congress 2013 on 28 September 2013
PARIS --(Business Wire)--
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the detailed
results of phase III CLARINET study assessing the effect of Somatuline®
Autogel® 120 mg in patients with gastrointestinal and
pancreatic neuroendocrine tumors ("GEP-NETs")1 will be
disclosed for the first time on September 28, 2013 at the European
Cancer Congress 2013 (Sept. 27 - Oct. 1, 2013) in Amsterdam.
CLARINET results will be presented by Prof. Philippe Ruszniewski, Head
Gastroenterology-Pancreatology Dept, Beaujon Hospital, Clichy, and Paris
Diderot University (France), one of the investigators of the study, to
the medical community on Saturday 28 September at 3:35pm (hall 7.1)
during Presidential Session I (1:45-3:55 pm). A press conference will be
held at 4:30pm (Emerald room), in presence notably of Marc de Garidel,
Chairman and CEO of Ipsen and of Prof. Philippe Ruszniewski.
The abstract number is LBA 3, "A randomized, double-blind,
placebo-Controlled study of Lanreotide Antiproliferative Response in
patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET)".
Ipsen is a global specialty-driven pharmaceutical company with total
sales exceeding €1.2 billion in 2012. Ipsen's ambition is to become a
leader in specialty healthcare solutions for targeted debilitating
diseases. Its development strategy is supported by 3 franchises:
neurology, endocrinology and uro-oncology. Moreover, the Group has an
active policy of partnerships. Ipsen's R&D is focused on its innovative
and differentiated technological platforms, peptides and toxins. In
2012, R&D expenditure totalled close to €250 million, representing more
than 20% of Group sales. The Group has close to 4,900 employees
worldwide. Ipsen's shares are traded on segment A of Euronext Paris
(stock code: IPN, SIN code: FR0010259150) and eligible to the "Service
de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index.
Ipsen has implemented a Sponsored Level I American Depositary Receipt
(ADR) program, which trade on the over-the-counter market in the United
States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
Forward Looking Statements
The forward-looking statements, objectives and targets contained herein
are based on the Group's management strategy, current views and
assumptions. Such statements involve known and unknown risks and
uncertainties that may cause actual results, performance or events to
differ materially from those anticipated herein. All of the above risks
could affect the Group's future ability to achieve its financial
targets, which were set assuming reasonable macroeconomic conditions
based on the information available today.
Moreover, the targets described in this document were prepared without
taking into account external growth assumptions and potential future
acquisitions, which may alter these parameters. These objectives are
based on data and assumptions regarded as reasonable by the Group. These
targets depend on conditions or facts likely to happen in the future,
and not exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain risks
and uncertainties, notably the fact that a promising product in early
development phase or clinical trial may end up never being launched on
the market or reaching its commercial targets, notably for regulatory or
competition reasons. The Group must face or might face competition from
Generics that might translate into a loss of market share.
Furthermore, the Research and Development process involves several
stages each of which involves the substantial risk that the Group may
fail to achieve its objectives and be forced to abandon its efforts with
regards to a product in which it has invested significant sums.
Therefore, the Group cannot be certain that favourable results obtained
during pre-clinical trials will be confirmed subsequently during
clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. The Group also depends on third parties to develop and market
some of its products which could potentially generate substantial
royalties; these partners could behave in such ways which could cause
damage to the Group's activities and financial results. The Group cannot
be certain that its partners will fulfil their obligations. It might be
unable to obtain any benefit from those agreements. A default by any of
the Group's partners could generate lower revenues than expected. Such
situations could have a negative impact on the Group's business,
financial position or performance.
The Group expressly disclaims any obligation or undertaking to update or
revise any forward looking statements, targets or estimates contained in
this press release to reflect any change in events, conditions,
assumptions or circumstances on which any such statements are based,
unless so required by applicable law.
The Group's business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des Marchés
1 GEP-NETs refer to gastro-entero-pancreatic neuroendocrine
[ Back To Technology News's Homepage ]